CY1114714T1 - USE OF DIFFERIPRON AND METHODS FOR THE TREATMENT AND / OR PREVENTION OF FRIEDREICH DISTRIBUTION Caused by Intracellular Iron Management - Google Patents

USE OF DIFFERIPRON AND METHODS FOR THE TREATMENT AND / OR PREVENTION OF FRIEDREICH DISTRIBUTION Caused by Intracellular Iron Management

Info

Publication number
CY1114714T1
CY1114714T1 CY20131101106T CY131101106T CY1114714T1 CY 1114714 T1 CY1114714 T1 CY 1114714T1 CY 20131101106 T CY20131101106 T CY 20131101106T CY 131101106 T CY131101106 T CY 131101106T CY 1114714 T1 CY1114714 T1 CY 1114714T1
Authority
CY
Cyprus
Prior art keywords
treatment
prevention
differipron
friedreich
iron
Prior art date
Application number
CY20131101106T
Other languages
Greek (el)
Inventor
Arnold Munnich
Michael Spino
Ioav Cabantchik
Original Assignee
Apotex Technologies Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07701800.0A external-priority patent/EP1991225B1/en
Application filed by Apotex Technologies Inc. filed Critical Apotex Technologies Inc.
Publication of CY1114714T1 publication Critical patent/CY1114714T1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Μία θεραπευτικά αποτελεσματική ποσότητα δεφεριπρόνης ή δεφερασιρόξ ή φυσιολογικά αποδεκτών αλάτων αυτών για την πρόληψη, σταθεροποίηση, θεραπεία ή αντιστροφή της προκαλούμενης από σίδηρο FRDA ασθένειας σε ασθενείς που προκύπτει από βλάβη που προκαλείται στα μιτοχόνδρια από σίδηρο για να ελαττώσει κατά προτίμηση τα αποθηκεύματα σιδήρου στα μιτοχόνδρια. Επίσης για την θεραπεία άλλων καταστάσεων που επηρεάζουν τον εγκέφαλο όπου το στοιχείο κλειδί για την δημιουργία της προκύπτουσας παθολογίας είναι ενδοκυτταρική κακή διαχείριση σιδήρου.A therapeutically effective amount of deferiprone or deferasirox or physiologically acceptable salts thereof for the prevention, stabilization, treatment or reversal of iron-induced FRDA disease in patients resulting from damage caused by iron mitochondria to reduced iron. Also for the treatment of other conditions affecting the brain where the key element in the creation of the resulting pathology is intracellular iron mismanagement.

CY20131101106T 2006-02-22 2013-12-09 USE OF DIFFERIPRON AND METHODS FOR THE TREATMENT AND / OR PREVENTION OF FRIEDREICH DISTRIBUTION Caused by Intracellular Iron Management CY1114714T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77532006A 2006-02-22 2006-02-22
EP07701800.0A EP1991225B1 (en) 2006-02-22 2007-02-21 The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron

Publications (1)

Publication Number Publication Date
CY1114714T1 true CY1114714T1 (en) 2016-10-05

Family

ID=58448786

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131101106T CY1114714T1 (en) 2006-02-22 2013-12-09 USE OF DIFFERIPRON AND METHODS FOR THE TREATMENT AND / OR PREVENTION OF FRIEDREICH DISTRIBUTION Caused by Intracellular Iron Management

Country Status (1)

Country Link
CY (1) CY1114714T1 (en)

Similar Documents

Publication Publication Date Title
MY151412A (en) The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
CY1124489T1 (en) HPK1 INHIBITORS AND METHODS OF USING THEREOF
CY1119939T1 (en) 2,3-Dihydro-Benzo [1,4] Oxazine Derivative and Related Compounds such as Phosphoinositin-3-Kinase (R3K) Inhibitors for Therapeutic Therapy
CY1117776T1 (en) SPIRIT-OXIDOLI COMPOUNDS ANTIOMETER AND THEIR USES AS A THERAPEUTIC AGENT
EA201991697A1 (en) SULFOXYMINE Glycosidase Inhibitors
CY1116333T1 (en) FUZZOURANI PRODUCERS AS FXR REGULATORY PARTS
EA201791981A1 (en) DERIVATIVES 4- (P-HINONIL) -2-HYDROXYBUTANAMIDE FOR THE TREATMENT OF MITOCHONDRIAL DISEASES
CY1108276T1 (en) COMPOUNDS THAT INFLUENCE Glycokinase
CY1124022T1 (en) DISTRIBUTION SCHEME FOR NITROCATECHOLS
CY1123216T1 (en) GLS1 INHIBITORS FOR THE TREATMENT OF DISEASE
CY1123914T1 (en) TREATMENT OF RAISED LEVELS OF EOSINOPHILS AND/OR BASEOPHILS
CR20150589A (en) BIHETEROARILO COMPOUNDS AND USES OF THE SAME
EA201391017A1 (en) METHODS AND READY MEDICATION FORMS FOR THE TREATMENT OF ALZHEYMER
CY1113450T1 (en) DIAMINOPYRIMIDINES AS P2X3 AND P2X2 / 3 COMPONENTS
ECSP13012611A (en) PIRAZOL-AMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF THE LRRK2
CY1120163T1 (en) METHODS OF ADMINISTRATION AND EVALUATION OF NITROGEN SCANNING MEDICINES FOR THE USEFUL HEALTH CARE TREATMENT
EA201690212A8 (en) METHODS OF TREATMENT OR PREVENTION OF OPHTHALMIC PATHOLOGICAL CONDITIONS
CY1114140T1 (en) 4-PYRIDINONE COMPONENTS AND THEIR USE FOR CANCER
ATE412636T1 (en) PIPERAZINYLPYRIDINE DERIVATIVES AS AN AGAINST OBESITY
AR088813A1 (en) METHOD FOR QUANTIFYING CANCER TREATMENT
DK3749308T3 (en) TREATMENT OF PATIENTS WITH CLASSIC FABRY'S DISEASE WITH MIGALASTAT
CY1106026T1 (en) ARYLSULFONAMIDES AS SEPOTONIN ANTAGONISTS FOR THE TREATMENT OF OBESITY
CY1116938T1 (en) HUNTINGTON AND OTHER POLYGLUTAMINE DISEASE REFUNDS
EA201071422A1 (en) METHODS OF TREATING DISEASES ASSOCIATED WITH MEIOTIC KINESIN
ES2540151A1 (en) Pharmaceutical composition of ibuprofen and tramadol for ophthalmic use (Machine-translation by Google Translate, not legally binding)